FDA hits Amicus with delay on 'breakthrough' Pompe drug

AT-GAA, Amicus Therapeutics’ lead Phase III drug for Pompe disease, was at the center of attention during the Q1 call with investors Monday. Execs talked about their high hopes for an approval by the July 29 PDUFA date, and analysts were asking questions about launch preparation.